$CUE

3 theses

bullish 33%neutral 0%bearish 67%

Avg return (1d)

-7.0%

Win rate (1d)

100% (1 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 18, 4:30 PM ET

$CUESEC 13Dbullish

Shao-Lee Lin · beneficial owner of Cue Biopharma, Inc. · 40d ago1 prior · awaiting results

Long 467,166 shares of CUE

467,166 shares · 6.2% of class · 2026-05-03

Schedule 13D: Shao-Lee Lin disclosed a stake in CUE

Shao-Lee Lin disclosed a 6.2% stake of 467,166 shares in Cue Biopharma, Inc. (CUE) in a Schedule 13D filed 2026-08-21.

At post $23.98Now $37.05+54.5% since postedas of Sep 18, 4:30 PM ET

1d—

3d-3.3%

1w+16.3%

1m—

3m—

6m—

1y—

View filing on SEC.gov →

$CUESEC Form 4bearish

Ray Sumita · Chief Legal Compliance Officer at Cue Biopharma, Inc. · 44d agono track record yet

Sold 8,829 @ $30.09 avg · $265,628 · 2026-08-13

Form 4: Ray Sumita sold CUE

Ray Sumita (Chief Legal Compliance Officer at Cue Biopharma, Inc.) reported an open-market sale of 8,829 shares of CUE at an average $30.09, roughly $265,628, in a Form 4 filed 2026-08-17.

At post $27.64Now $37.05+34.0% since postedas of Sep 18, 4:30 PM ET

1d-7.0%

3d-11.0%

1w-16.1%

1m+23.6%

3m—

6m—

1y—

View filing on SEC.gov →

$CUESEC Form 4bearish

Lin Shao-Lee · Chief Executive Officer at Cue Biopharma, Inc. · 47d ago1 prior · awaiting results

Sold 58,258 @ $27.58 avg · $1,606,562 · 2026-08-12

Form 4: Lin Shao-Lee sold CUE

Lin Shao-Lee (Chief Executive Officer at Cue Biopharma, Inc.) reported an open-market sale of 58,258 shares of CUE at an average $27.58, roughly $1,606,562, in a Form 4 filed 2026-08-14.

At post $34.20Now $37.05+8.3% since postedas of Sep 18, 4:30 PM ET

1d—

3d-19.2%

1w-29.9%

1m-16.0%

3m—

6m—

1y—

View filing on SEC.gov →

End of results.